Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16771700 | 1.00 | ARG1 (0.38) | ARG1MALT1HTTGLA | |
| SCHEMBL16771693 | 1.00 | ARG1 (0.38) | ARG1MALT1HTTGLA | |
| Hydrochloric Acid SCHEMBL15573124 | 0.98 | ARG1 (0.38) | ARG1MALT1HTTGLA | |
| Hydrochloric Acid SCHEMBL16759537 | 0.98 | ARG1 (0.38) | ARG1MALT1HTTGLA | |
| Hydrochloric Acid SCHEMBL18259318 | 0.98 | ARG1 (0.38) | ARG1MALT1HTTGLA | |
| Hydrochloric Acid SCHEMBL20453849 | 0.86 | ARG1 (0.38) | ARG1 | |
| SCHEMBL2380650 | 0.84 | ARG1 (0.35) | ARG1MALT1 | |
| SCHEMBL1854210 | 0.84 | ARG1 (0.38) | ARG1MALT1 | |
| SCHEMBL30301492 | 0.84 | ARG1 (0.38) | ARG1MALT1 | |
| Hydrochloric Acid SCHEMBL11540995 | 0.82 | ARG1 (0.37) | ARG1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226287-A1 | NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3122747-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| EP-3074394-B1 | PROCESSES FOR PREPARING DIHYDROPYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-02-20 | — | — | EP | disclosed |
| EP-2007857-A1 | USE OF RYLENES AS MARKERS FOR LIQUIDS | BASF SE (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-7365067-B2 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| EP-1904497-A1 | SUBSTITUTED RYLENE DERIVATIVES | BASF SE (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007099059-A1 | USE OF RYLENES AS MARKERS FOR LIQUIDS | BASF SE (DE) | 2007-09-07 | — | — | WO | disclosed |
| US-20070197570-A1 | Indanol derivative | SANKYO COMPANY, LIMITED (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1819678-A1 | RYLENE TETRACARBOXYLIC ACID DIIMIDES SUBSTITUTED BY CYCLIC AMINO GROUPS | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-22 | — | — | EP | disclosed |
| EP-1746095-A1 | INDANOL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-01-24 | — | — | EP | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| EP-0730591-B1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | UPJOHN CO (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5763631-A | CIS-EPOXIDE COMPOUNDS; ANTIVIRUS AGENTS; USEFUL TO TREAT THE AIDS | LUCKY LIMITED (KR) | 1998-06-09 | — | — | US | disclosed |
| US-5744621-A | CIS-EPOXIDE COMPOUNDS | LUCKY LIMITED. (KR) | 1998-04-28 | — | — | US | disclosed |
| US-5652238-A | WATER SOLUBILITY; ANTIMICROBIAL AGENTS EFFECTIVE AGAINST RESISTANT STAPHYLOCOCCI, ENTEROCOCCI, AND STREPTOCOCCI | PHARMACIA & UPJOHN COMPANY (US) | 1997-07-29 | — | — | US | disclosed |
| US-5587388-A | AIDS; VIRICIDES | LUCKY LIMITED (KR) | 1996-12-24 | — | — | US | disclosed |
| EP-0730591-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | PHARMACIA & UPJOHN COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014684-A1 | ESTERS OF SUBSTITUTED-HYDROXYACETYL PIPERAZINE PHENYL OXAZOLIDINONES | THE UPJOHN COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0601486-A1 | Cis-epoxide derivatives useful as irreversible HIV protease inhibitors and process and intermediates for their preparation | LUCKY LTD. (KR) | 1994-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197570-A1 | Indanol derivative | BDKRB2, BDKRB1, TACR2 | ARG1 229/4885MALT1 3405/4885HTT 3799/4885 |
| US-20240226287-A1 | NOVEL LIPID COMPOUND AND LIPID NANOPARTICLE COMPOSITION COMPRISING THE SAME | HDLBP, LRAT, CETP | ARG1 2781/4885MALT1 4427/4885HTT 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.